AquaBounty Technologies is conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. Co. has the licensing rights for a gene construct (transgene) used to create a breed of farm-raised Atlantic salmon. Co. has obtained regulatory approval from the U.S. Food and Drug Administration for the production and sale of its genetically engineered AquAdvantage salmon product (GE Atlantic salmon) in the U.S.; from Health Canada for the production and sale of its GE Atlantic salmon product in Canada; and from National Biosafety Technical Commission for the sale of its GE Atlantic salmon product in Brazil. We show 25 historical shares outstanding datapoints in our coverage of AQB's shares outstanding history.
Understanding the changing numbers of AQB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AQB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AQB by allowing them to research AQB shares outstanding history
as well as any other stock in our coverage universe. |